Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis

TURGUT, Sevil; Şahin, Mehmet Ali; BODUR, Şahin; TASKİRAN, Candan; ERSÖZ ALAN, BURCU; Kara, Halil; CETİNKAYA, Miray; Işıldar, Yetiş

Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis

Şahin BODUR, (Dr. Sami Ulus Çocuk Sağlığı ve Hastalıkları Eğitim ve Araştırma Hastanesi, Çocuk ve Ergen Psikiyatrisi Kliniği, Ankara, Türkiye)

Candan TASKİRAN, (Dr. Sami Ulus Çocuk Sağlığı ve Hastalıkları Eğitim ve Araştırma Hastanesi, Çocuk ve Ergen Psikiyatrisi Kliniği, Ankara, Türkiye)

Yetiş IŞILDAR, (Dr. Sami Ulus Çocuk Sağlığı ve Hastalıkları Eğitim ve Araştırma Hastanesi, Çocuk ve Ergen Psikiyatrisi Kliniği, Ankara, Türkiye)

BURCU ERSÖZ ALAN, (Kırıkkale Üniversitesi, Tıp Fakültesi, Psikiyatri Anabilim Dalı, Kırıkkale, Türkiye)

Miray CETİNKAYA, (Dr. Münif İslamoğlu Kastamonu Devlet Hastanesi, Kastamonu, Türkiye)

Halil KARA, (Boş)

Mehmet ŞAHİN, (Boş)

Sevil TURGUT (Akdeniz Üniversitesi, Tıp Fakültesi, Nöroloji Anabilim Dalı, Antalya, Türkiye)

Klinik Psikofarmakoloji Bülteni

1 0

Yıl: 2016 Cilt: 26 Sayı: 3 Sayfa Aralığı: 273 - 277 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis

Öz:

Objective: The aim of the present study is to specify the frequency in psychopharmacological medication use in children with autism spectrum disorder (ASD) and determine their age range at diagnosis. Methods: Five hundred and twenty three children with ASD who applied to Dr. Sami Ulus Maternity and Children Research and Training Hospital between 2010 -2015 were reviewed retrospectively. Data has been obtained from computerized hospital information system. Individuals with the diagnosis of Autism (F84.0), Atypical Autism (F84.1) and Pervasive Developmental Disorder Not Other Specified (F84.9) were screened. Results: Psychotropic medication was recommended to 28.5% of the 523 children and adolescents diagnosed with ASD. Antipsychotics were the most common drugs of choice among psychotropic medications. The mean age at diagnosis of patients taking psychotropic medication was significantly higher than that of the patients who were not taking psychotropic medication (t=-3.064; p<0.01). The rate of psychotropic drug usage in female patients was significantly high than male patients (?²=6.675; p=0.01).Conclusion: The results of the present study suggest that the delay of diagnosis can be included as a factor for psychotropic medication need of patients with ASD. Nearly half of the patients have been diagnosed in the first three years of their life. For further benefits of studies in Turkey, evaluating the psychopharmacological drug prescription rate, age of diagnosis and related factors to determine the present situation of psychotropic medication in our country will be necessary

Anahtar Kelime:

Konular: Farmakoloji ve Eczacılık

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Lai MC, Lombardo MV, Baron-Cohen S. Autism. Lancet 2014;383(9920):896-910. [CrossRef]2. Developmental Disabilities Monitoring Network Surveillance Year 2010 Principal Investigators; Centers for Disease Control and Prevention (CDC). Prevalence of autism spectrum disorder among children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, United States, 2010. MMWR Surveill Summ 2014;28;63(2):1-21.3. Anagnostou E, Zwaigenbaum L, Szatmari P, Fombonne E, Fernandez BA, Woodbury-Smith M, et al. Autism spectrum disorder: advances in evidence-based practice. CMAJ 2014;15;186(7):509-19.4. Monteiro SA, Spinks-Franklin A, Treadwell-Deering D, Berry L, Sellers-Vinson S, Smith E, et al. Prevalence of Autism Spectrum Disorder in Children Referred for Diagnostic Autism Evaluation. Clin Pediatr (Phila) 2015;54(14):1322-7. [CrossRef] 5. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr Res 2009;65(6):591-8. [CrossRef]6. Fombonne E, Quirke S, Hagen A. Epidemiology of pervasive developmental disorders. In Amaral D, Dawson G, Geschwind D, eds. Autism Spectrum Disorders. New York: Oxford University Press; 2011. p. 90-111. [CrossRef]7. Lai MC, Lombardo MV, Auyeung B, Chakrabarti B, Baron-Cohen S. Sex/gender differences and autism: setting the scene for future research. J Am Acad Child Adolesc Psychiatry 2015;54(1):11-24. [CrossRef]8. Volkmar FR, Wiesner LA. Autism and Related Disorders. In: Carey EB, Crocker AC, Coleman WL, Elias ER, Feldman HM, eds. Developmental-Behavioral Pediatrics, 4th edn. Philadelphia: Saunders; 2009:675-85. [CrossRef]9. Costanzo V, Chericoni N, Amendola FA, Casula L, Muratori F, Scattoni ML, et al. Early detection of autism spectrum disorders: From retrospective home video studies to prospective 'high risk' sibling studies. Neurosci Biobehav Rev 2015;55:627-35. [CrossRef]10. Zwaigenbaum L, Bryson S, Garon N. Early identification of autism spectrum disorders. Behav Brain Res 2013;15;251:133-46. [CrossRef]11. Kleinman JM, Robins DL, Ventola PE, Pandey J, Boorstein HC, Esser EL, et al. The modified checklist for autism in toddlers: a follow-up study investigating the early detection of autism spectrum disorders. J Autism Dev Disord 2008;38(5):827-39. [CrossRef]12. Chlebowski C, Robins DL, Barton ML, Fein D. Large-scale use of the modified checklist for autism in low-risk toddlers. Pediatrics 2013;131(4):e1121-7. [CrossRef]13. Zwaigenbaum L, Bauman ML, Fein D, Pierce K, Buie T, Davis PA, et al. Early Screening of Autism Spectrum Disorder: Recommendations for Practice and Research. Pediatrics 2015;136 Suppl 1:S41-59. [CrossRef]14. Robins DL, Casagrande K, Barton M, Chen CM, Dumont-Mathieu T, Fein D. Validation of the modified checklist for Autism in toddlers, revised with follow-up (M-CHAT-R/F). Pediatrics 2014;133(1):37-45. [CrossRef]15. Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; 17;10:CD009260. [CrossRef]16. Politte LC, Henry CA, McDougle CJ. Psychopharmacological interventions in autism spectrum disorder. Harv Rev Psychiatry 2014;22(2):76-92. [CrossRef]17. Persico AM, Arango C, Buitelaar JK, Correll CU, Glennon JC, Hoekstra PJ, et al. Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives. Eur Neuropsychopharmacol 2015;25(10):1513-31. [CrossRef]18. Wong AY, Hsia Y, Chan EW, Murphy DG, Simonoff E, Buitelaar JK, et al. The variation of psychopharmacological prescription rates for people with autism spectrum disorder (ASD) in 30 countries. Autism Res 2014;7(5):543-54. [CrossRef]19. Baribeau DA, Anagnostou E. An update on medication management of behavioral disorders in autism. Curr Psychiatry Rep 2014;16(3):437. [CrossRef]20. Steckler T, Spooren W, Murphy D. Autism spectrum disorders--an emerging area in psychopharmacology. Psychopharmacology (Berl) 2014;231(6):977-8. [CrossRef]21. Stigler KA. Psychopharmacologic management of serious behavioral disturbance in ASD. Child Adolesc Psychiatr Clin N Am 2014;23(1):73-82. [CrossRef]22. Cadman T, Eklund H, Howley D, Hayward H, Clarke H, Findon J, et al. Caregiver burden as people with autism spectrum disorder and attention-deficit/hyperactivity disorder transition into adolescence and adulthood in the United Kingdom. J Am Acad Child Adolesc Psychiatry 2012;51(9):879-88. [CrossRef]23. Hsia Y, Wong AY, Murphy DG, Simonoff E, Buitelaar JK, Wong IC. Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. Psychopharmacology (Berl) 2014;231(6):999-1009. [CrossRef]24. Aras S, Varol-Tas F, Unlü G. Alterations in medication in a child and adolescent psychiatric outpatient clinic. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2005;15(3):127-33. (Turkish)25. Gurkan K, Soykan-Aysev A, Akcakin M. Pharmacological management of pervasive developmental disorders. Klinik Psikofarmakoloji Bulteni - Bulletin of Clinical Psychopharmacology 2005;15(2):53-9. (Turkish)26. Ulay HT, Kultur SEC. Medication patterns in children with pervasive developmental disorders. Turk J Child Adolesc Ment Health 2006;13(3):117-23. (Turkish)27. Dogan BS, Cak TH, Kultur SEC. The frequency of psychotropic medication use, distribution and associated variables in children diagnosed with uutistic spectrum disorder. Turk J Child Adolesc Ment Health 2014;21(2):105-14. (Turkish)28. Osborne LA, Reed P. Parents' perceptions of communication with professionals during the diagnosis of autism. Autism 2008;12(3):309-24. [CrossRef]29. Fountain C, King MD, Bearman PS. Age of diagnosis for autism: individual and community factors across 10 birth cohorts. J Epidemiol Community Health 2011;65(6):503-10. [CrossRef]30. Murray ML, Hsia Y, Glaser K, Simonoff E, Murphy DG, Asherson PJ, et al. Pharmacological treatments prescribed to people with autism spectrum disorder (ASD) in primary health care. Psychopharmacology (Berl) 2014;231(6):1011-21. [CrossRef]31. Aman MG, Lam KS, Van Bourgondien ME. Medication patterns in patients with autism: temporal, regional, and demographic influences. J Child Adolesc Psychopharmacol 2005;15(1):116-26. [CrossRef]32. Oswald DP, Sonenklar NA. Medication use among children with autism spectrum disorders. J Child Adolesc Psychopharmacol 2007;17(3):348-55. [CrossRef]

APA	BODUR Ş, TASKİRAN C, Işıldar Y, ERSÖZ ALAN B, CETİNKAYA M, Kara H, Şahin M, TURGUT S (2016). Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. , 273 - 277.
Chicago	BODUR Şahin,TASKİRAN Candan,Işıldar Yetiş,ERSÖZ ALAN BURCU,CETİNKAYA Miray,Kara Halil,Şahin Mehmet Ali,TURGUT Sevil Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. (2016): 273 - 277.
MLA	BODUR Şahin,TASKİRAN Candan,Işıldar Yetiş,ERSÖZ ALAN BURCU,CETİNKAYA Miray,Kara Halil,Şahin Mehmet Ali,TURGUT Sevil Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. , 2016, ss.273 - 277.
AMA	BODUR Ş,TASKİRAN C,Işıldar Y,ERSÖZ ALAN B,CETİNKAYA M,Kara H,Şahin M,TURGUT S Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. . 2016; 273 - 277.
Vancouver	BODUR Ş,TASKİRAN C,Işıldar Y,ERSÖZ ALAN B,CETİNKAYA M,Kara H,Şahin M,TURGUT S Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. . 2016; 273 - 277.
IEEE	BODUR Ş,TASKİRAN C,Işıldar Y,ERSÖZ ALAN B,CETİNKAYA M,Kara H,Şahin M,TURGUT S "Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis." , ss.273 - 277, 2016.
ISNAD	BODUR, Şahin vd. "Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis". (2016), 273-277.

APA	BODUR Ş, TASKİRAN C, Işıldar Y, ERSÖZ ALAN B, CETİNKAYA M, Kara H, Şahin M, TURGUT S (2016). Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. Klinik Psikofarmakoloji Bülteni, 26(3), 273 - 277.
Chicago	BODUR Şahin,TASKİRAN Candan,Işıldar Yetiş,ERSÖZ ALAN BURCU,CETİNKAYA Miray,Kara Halil,Şahin Mehmet Ali,TURGUT Sevil Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. Klinik Psikofarmakoloji Bülteni 26, no.3 (2016): 273 - 277.
MLA	BODUR Şahin,TASKİRAN Candan,Işıldar Yetiş,ERSÖZ ALAN BURCU,CETİNKAYA Miray,Kara Halil,Şahin Mehmet Ali,TURGUT Sevil Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. Klinik Psikofarmakoloji Bülteni, vol.26, no.3, 2016, ss.273 - 277.
AMA	BODUR Ş,TASKİRAN C,Işıldar Y,ERSÖZ ALAN B,CETİNKAYA M,Kara H,Şahin M,TURGUT S Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. Klinik Psikofarmakoloji Bülteni. 2016; 26(3): 273 - 277.
Vancouver	BODUR Ş,TASKİRAN C,Işıldar Y,ERSÖZ ALAN B,CETİNKAYA M,Kara H,Şahin M,TURGUT S Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis. Klinik Psikofarmakoloji Bülteni. 2016; 26(3): 273 - 277.
IEEE	BODUR Ş,TASKİRAN C,Işıldar Y,ERSÖZ ALAN B,CETİNKAYA M,Kara H,Şahin M,TURGUT S "Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis." Klinik Psikofarmakoloji Bülteni, 26, ss.273 - 277, 2016.
ISNAD	BODUR, Şahin vd. "Factors Affecting Burden of Psychopharmacological Medication in Patients with Autism Spectrum Disorder: The Importance of Early Diagnosis". Klinik Psikofarmakoloji Bülteni 26/3 (2016), 273-277.